Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
France Targets Shein, Temu With Fast-Fashion Fees 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Rejects Apple Trade Secret Theft Claims 
Add as a preferred source on Google
BUENA, N.J., March 05, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James 39th Annual Institutional Investors Conference. The Conference is taking place March 4-7, 2018 at the J.W. Marriott Grande Lakes, Orlando, FL.
Jason Grenfell-Gardner, President and CEO and Damian Finio, Chief Financial Officer of Teligent, Inc. will present on Wednesday March 7th at 9:15 a.m. ET.
The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.teligent.com. A replay will be available for 30 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Martin Wilson
Teligent, Inc.
856-336-9120
www.teligent.com
